Daewoong Holds KOL Summit in Bali
As Daewoong Pharmaceutical’s botulinum toxin product 'Nabota' expands its market dominance after surpassing KRW 1 trillion ($714.29 million) in cumulative global sales, key medical professionals from around the world gathered in one place to discuss advanced procedure techniques.Daewoong Pharmaceuti
In October 29-31, Daewoong Pharmaceutical hosted the NMC EXCLUSIVE Global KOL Summit Bali 2026 in Indonesia. The summit aimed to educate key opinion leaders (KOLs) from 11 countries on advanced Nabota procedure techniques. The three-day event was a progression from the existing Nabota Master Class (NMC) program, with 35 carefully selected KOLs attending.
The FDA-approved Nabota has seen a 57% average annual sales growth since 2019, with cumulative global sales reaching KRW 1 trillion ($714.29 million) as of June. During the summit, KOLs from South Korea, Indonesia, Saudi Arabia, and Brazil discussed Nabota use cases for upper facial wrinkles, body contouring, migraines, and other areas.
On the second day, Dr. Alexander Nassif of Brazil introduced a decision-making process for facial treatment based on anatomy, while Dr. Anisia Tania of Indonesia presented Nabota-specific procedures like Nabolift and Naboglow. The summit also provided KOLs a chance to network at Daewoong Group’s BWork Uluwatu co-working space and the NULOOK Clinic.
Daewoong Pharmaceutical CEO Yoon Joon-soo stated that the event's success stems from Nabota's strong global market presence and that the company will continue to offer specialized educational programs to further develop medical professionals' expertise.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
